Making rare disease drug development personal

The statistics regarding rare diseases speak for themselves: one of two patients diagnosed with a rare disease is a child; three of 10 children with a rare disease won’t live to see their fifth birthday; more than 400 million people suffer from a rare disease globally — greater than the population of the U.S. Fortunately, the drug development landscape for rare diseases is increasing exponentially. However, there are many challenges in conducting rare disease clinical trials, including small populations often spread across the globe, limited opportunities for study participation and replication of results in larger trials, and heterogeneous manifestations of disease and phenotypic presentations. The clinical manifestations are often not easily connected to a specific disease — on average, a rare disease patient visits seven specialists, and a correct diagnosis can take as long as six to eight years — and a lack of consensus on clinical outcome measures and poorly defined endpoints.

In this article, Shipra Patel, M.D., Global TA Section Head, Endocrinology, Parexel, discusses how she strives to overcome these challenges daily.


Open PDF

Return to Insights Center

Related Insights

Podcast

Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training

Jun 28, 2024

Podcast

De-risking Drug Development | Episode 1: How to drive value in pre-clinical development

May 28, 2024

Podcast

Enabling Successful Sites, Ep3: Taking the complexity out of oncology clinical trials

Jun 28, 2024

Playbook

Insights from the 2022 R&D Innovation Survey

Feb 17, 2023

Blog

Parexel names first Patient Ambassador

Jun 17, 2022

Article

EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022

Webinar

China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022

Blog

Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence

Aug 10, 2022

Podcast

Why Rare Disease Therapeutics Need Early Market Access Planning

Jan 4, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

Studying rare cancer patient populations using integrated genomic and real-world data

Aug 30, 2023